Results from the 80-patient study showed that 54 percent of diabetic wounds in the intent-to-treat population receiving the high dose of DSC127 achieved 100 percent closure in 12 weeks or less, compared with 33 percent of patients receiving placebo control and 30 percent of patients receiving the low dose of DSC127

The trial will enroll 160 patients receiving chemoradiotherapy for head and neck cancer, randomized to four treatment arms: placebo and three different doses of SCV-07

Patients receiving such transplants are typically at risk for graft-vs.-host disease, as well as other complications

In the study, patients receiving 10 million to 15 million cells improved significantly in resting perfusing rates at six months compared to patients receiving 5 million cells

In the study, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in acute coronary syndrome patients receiving coronary stents

As previously reported, patients receiving Folotyn had a 16 percent reduction in the risk of death compared to Tarceva in the overall population, with a hazard ratio of 0.84

Generex Biotechnology Corp., of Worcester, Mass., said data from an ongoing Phase II trial of its breast cancer vaccine, AE37, showed that patients receiving AE37 and Herceptin (trastuzumab, Genentech Inc./Roche AG) simultaneously showed an increase in specific immune stimulation of T cells compared to AE37 given after trastuzumab therapy

Shire plc, of Dublin, Ireland, said top-line results from the Phase III FAST-3 (For Angioedema Subcutaneous Treatment) trial of Firazyr (icatibant), a specific bradykinin B2 receptor antagonist, in acute attacks of hereditary angioedema (HAE) showed that patients receiving treatment experienced a significantly faster time to onset of symptom relief from individual and combined cutaneous and abdominal HAE symptoms, compared to placebo

Hemispherx Biopharma Inc., of Philadelphia, Penn., reported that in a Phase III trial of its investigational drug Ampligen, being developed for chronic fatigue syndrome, patients receiving Ampligen twice weekly had a reduced incidence of prolonged QT interval...About 60 percent of the patients receiving bardoxolone methyl experienced a reduction in the classification of the severity of their disease after 24 weeks of treatment. (See BioWorld Today, Sept. 24, 2010

Data also showed that patients receiving SOC therapies required splenectomies earlier when compared to the Nplate arm, and Nplate-treated patients also experienced increased platelet counts, higher platelet response rates, less bleeding and fewer blood transfusions...At seven days of therapy 44.6 percent (37/83) of patients receiving JNJ-Q2 were assessed as cured compared to 35.9 percent (28/78) of patients receiving linezolid, while 66.3 percent (55/83) of patients in the JNJ-Q2 arm were assessed

The Phase II portion will consist of two independent arms testing PX-866 plus docetaxel in patients with specific tumor types, with one arm including patients receiving second- or third-line treatment for non-small-cell lung cancer and the second arm including patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck

GBM patients receiving trabedersen locally via an intratumoral catheter had long-term survival rates at two years and three years that were three times higher than those of patients who received standard chemotherapy

About 50 percent of patients receiving Traficet-EN in the maintenance period were in clinical remission by the end of 36 weeks compared to 31 percent of patients on placebo

Optimer Pharmaceuticals Inc., of San Diego, said combined data from its two fidaxomicin Phase III trials in patients with Clostridium difficile infection showing global cure rates of 75 percent for the fidaxomicin group compared to 63 percent for patients receiving vancomycin (p < 0.001

Patients receiving Cayston had an adjusted mean actual increase in FEV1 percent predicted from baseline over six months of 2.05 percent compared to a 0.66 percent decrease for patients receiving tobramycin

plc, of Dublin, Ireland, reported data further supporting the potential clinical use of an investigational assay detecting anti-JC virus antibodies in human plasma or serum, which may provide a means to segment multiple sclerosis patients receiving Tysabri (natalizumab) treatment

An observational study showed a 50 percent survival rate in patients receiving Tamiflu within six to eight days of symptom onset, compared to 80 percent survival for those receiving the drug within two days and 20 percent survival for those who did not get treatment

Titan Pharmaceuticals Inc., of South San Francisco, said data from its Phase III trial of Probuphine showed that patients receiving the implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study...Patients receiving Probuphine had a mean percentage of urine samples that tested negative for illicit opioids across the full

Patients receiving 400-mg I.V